Jazz Pharmaceuticals (FRA:J7Z) Other Income (Expense) : €-9 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Other Income (Expense)?

Jazz Pharmaceuticals's other income expense for the Jazz Pharmaceuticals's pretax income for the three months ended in Dec. 2023 was €-8 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-9 Mil.

Jazz Pharmaceuticals Other Income (Expense) Historical Data

The historical data trend for Jazz Pharmaceuticals's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Other Income (Expense) Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

Get a 7-Day Free Trial

-104.21

-321.12

-3.85

-563.39

-9.37

Jazz Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Income (Expense)	Get a 7-Day Free Trial															-356.34	2.05	-2.20	-1.29	-7.93

Jazz Pharmaceuticals Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9 Mil.

Jazz Pharmaceuticals (FRA:J7Z) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Jazz Pharmaceuticals (FRA:J7Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

JAZZ:USA JAZZ:Mexico

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines